Last reviewed · How we verify
Vifor
At a glance
| Generic name | Vifor |
|---|---|
| Also known as | an iron-supplemented group |
| Sponsor | Kunshan First People's Hospital Affiliated to Jiangsu University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Perioperative Management in Gynaecological Carcinoma Surgery (PHASE3)
- Bioequivalence Study of Iron Sucrose Injection in Healthy Participants (PHASE1)
- Treatment of Ulcerative Colitis With Rectal Instillation of Qinghua Quyu Prescription(QHQYP) (NA)
- Patiromer Trial in CKD Stage IIIB to V (PHASE3)
- The Role of Intravenous Ferritin in Optimizing Postoperative Recovery Following Pancreaticoduodenectomy (NA)
- IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency (PHASE3)
- Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia (PHASE1)
- Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vifor CI brief — competitive landscape report
- Vifor updates RSS · CI watch RSS
- Kunshan First People's Hospital Affiliated to Jiangsu University portfolio CI